T1b期声门型鳞状细胞癌治疗中的治疗方式与肿瘤学结局:一项系统评价
Therapeutic modalities and oncologic outcomes in the treatment of T1b glottic squamous cell carcinoma: a systematic review.
作者信息
Gioacchini Federico Maria, Tulli Michele, Kaleci Shaniko, Bondi Stefano, Bussi Mario, Re Massimo
机构信息
ENT Unit, Department of Clinical and Molecular Sciences, Ospedali Riuniti of Ancona, Polytechnic University of Marche, Via Conca 71, 60020, Ancona, Italy.
Department of Otorhinolaryngology, San Raffaele Scientific Institute, Milan, Italy.
出版信息
Eur Arch Otorhinolaryngol. 2017 Dec;274(12):4091-4102. doi: 10.1007/s00405-017-4736-z. Epub 2017 Sep 19.
T1a and T1b glottic squamous cell carcinoma (SCC) are often analyzed together by authors who investigate the oncologic outcomes achieved after different therapeutic options. Nevertheless, T1b definitely represents a more advanced tumor stage compared to T1a glottic SCC. The objective of this review was first to analyze the overall success rates in the treatment of patients affected by T1b glottic SCC. Moreover, a subgroup analysis was planned to specifically compare the outcomes obtained with radiotherapy (RT), transoral laser microsurgery (TLM) and open partial laryngectomies (OPL). An electronic library search of the relevant English literature was performed. Potentially eligible articles were reviewed. Qualified articles were selected and evaluated. Fifty-two studies comprising 2360 patients were included. The overall rate of disease-free survival (DFS) was 85% (95% CI 83-87). The overall rate of overall survival was 85% (95% CI 80-88) while the rate of disease-specific survival (DSS) was found to be 96% (95% CI 90-98). Statistical data concerning outcomes for each therapeutic modality showed an higher DFS rate for subjects treated with RT and OPL, respectively, 87% (95% CI 0.85-0.89) and 83% (95% CI 0.78-0.89), when compared to those who underwent TLM 77% (95% CI 0.69-0.83). In conclusion, our results showed a high level of overall DSS (96%) for patients affected by T1b glottic SCC. Regarding the specific therapeutic options, our subgroup analysis showed as patients treated with TLM present a higher rate of oncological recurrence in comparison to those who underwent RT or OPL. Nevertheless, on the basis of our data it was also noted that no significant differences subsist in terms of survival rates among the three different treatments. Moreover, the absence of a comparative analysis useful to confirm these conclusions must be considered.
T1a和T1b期声门鳞状细胞癌(SCC)常被研究不同治疗方案后肿瘤学结局的作者放在一起分析。然而,与T1a期声门SCC相比,T1b期无疑代表了更晚期的肿瘤阶段。本综述的目的首先是分析T1b期声门SCC患者治疗的总体成功率。此外,计划进行亚组分析,以具体比较放射治疗(RT)、经口激光显微手术(TLM)和开放性部分喉切除术(OPL)的治疗结果。对相关英文文献进行了电子图书馆检索。对潜在符合条件的文章进行了综述。挑选并评估了合格的文章。纳入了52项研究,共2360例患者。无病生存率(DFS)的总体率为85%(95%CI 83-87)。总生存率的总体率为85%(95%CI 80-88),而疾病特异性生存率(DSS)为96%(95%CI 90-98)。每种治疗方式结局的统计数据显示,与接受TLM治疗的患者(77%,95%CI 0.69-0.83)相比,接受RT和OPL治疗的患者DFS率分别更高,为87%(95%CI 0.85-0.89)和83%(95%CI 0.78-0.89)。总之,我们的结果显示,T1b期声门SCC患者的总体DSS水平较高(96%)。关于具体的治疗选择,我们的亚组分析显示,与接受RT或OPL治疗的患者相比,接受TLM治疗的患者肿瘤复发率更高。然而,根据我们的数据还注意到,三种不同治疗方法在生存率方面不存在显著差异。此外,必须考虑缺乏有助于证实这些结论的比较分析。